Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 9 EP applications Dawn Caroline Goff has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after February 24, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12838132

ANTIBACTERIAL COMPOUNDS

IPC classification:
A01N 57/00
Applicant:
Glaxo Group Limited
Applicant:
Shionogi & Co. Limited (Shionogi Seiyaku Kabushiki-gaisha)
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
PATENT GRANTED
EP12859359

METHOD OF TREATING CANCER WITH MAGEA3 IMMUNOTHERAPEUTIC WITH BRAF INHIBITOR AND/OR MEK INHIBITOR

IPC classification:
A01N 43/40, A61K 31/54, A61K 39/00
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13743888

ANTACID TABLET

IPC classification:
A61K 33/10
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP13718590

NOVEL COMPOUNDS

IPC classification:
A61K 31/18, A61P 11/06, A61P 17/06, C07C 311/21, C07C 311/29, C07C 311/44, C07D 205/04, C07D 207/08, C07D 239/54, C07D 265/30, C07D 265/32, C07D 309/04, C07D 309/06, C07D 309/10, C07D 319/12
Applicant:
Glaxo Group Limited
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13835019

METHOD OF ADJUVANT CANCER TREATMENT

IPC classification:
A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Applicant:
GlaxoSmithKline LLC
Agent:
Sewkian Rudge, Novartis Pharma AG
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13820853

2 SUBSTITUTED CEPHEM COMPOUNDS

IPC classification:
A61K 31/546, C07D 501/50, C07D 505/24
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP11831214

BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

IPC classification:
A01N 43/52, A61K 31/4164, C07D 235/08, C07D 235/10, C07D 235/24, C07D 401/10, C07D 403/04, C07D 403/10, C07D 405/04, C07D 405/10, C07D 409/10, C07D 413/04, C07D 413/10, C07D 417/04, C07D 417/10, C07D 513/04
Applicant:
GlaxoSmithKline LLC
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
PATENT GRANTED
EP14846138

COMBINATION DRUG THERAPY

IPC classification:
A61K 31/4166, A61K 31/535, C07D 233/86, C07D 413/10
Applicant:
GlaxoSmithKline LLC
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14809779

NOVEL MILK BEVERAGE COMPOSITION COMPRISING CREATINE

IPC classification:
A23C 9/152, A23C 9/154, A23C 11/10
Applicant:
Glaxo Group Limited
Agent:
Dawn Caroline Goff, GlaxoSmithKline
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature